$1.40 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter

Share on StockTwits

Brokerages expect Charles River Laboratories Intl. Inc (NYSE:CRL) to post $1.40 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with estimates ranging from $1.32 to $1.48. Charles River Laboratories Intl. posted earnings per share of $1.38 during the same quarter last year, which indicates a positive year over year growth rate of 1.4%. The company is expected to report its next quarterly earnings results on Thursday, May 9th.

On average, analysts expect that Charles River Laboratories Intl. will report full year earnings of $6.48 per share for the current year, with EPS estimates ranging from $6.45 to $6.51. For the next fiscal year, analysts anticipate that the company will report earnings of $7.36 per share, with EPS estimates ranging from $7.22 to $7.46. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 13th. The medical research company reported $1.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.10. The company had revenue of $605.53 million during the quarter, compared to analysts’ expectations of $589.86 million. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. Charles River Laboratories Intl.’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.40 EPS.

A number of research firms recently commented on CRL. Barclays reiterated a “hold” rating and set a $135.00 price target on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. SunTrust Banks lifted their price target on Charles River Laboratories Intl. to $151.00 and gave the stock a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 price target for the company in a report on Thursday, February 14th. Jefferies Financial Group reiterated a “buy” rating and set a $162.00 price target on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. Finally, Morgan Stanley lifted their price target on Charles River Laboratories Intl. from $112.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, December 3rd. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Charles River Laboratories Intl. has a consensus rating of “Buy” and a consensus price target of $140.21.

In other Charles River Laboratories Intl. news, Chairman James C. Foster sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $115.00, for a total value of $2,875,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert J. Bertolini sold 3,440 shares of the stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $133.77, for a total transaction of $460,168.80. Following the completion of the sale, the director now owns 29,876 shares in the company, valued at $3,996,512.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,417 shares of company stock valued at $3,590,419. 2.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of CRL. Advisors Asset Management Inc. grew its holdings in shares of Charles River Laboratories Intl. by 41.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 11,686 shares of the medical research company’s stock valued at $1,312,000 after purchasing an additional 3,396 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Charles River Laboratories Intl. by 34.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 5,545 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 1,425 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Charles River Laboratories Intl. by 1,910.1% during the 3rd quarter. Bank of Montreal Can now owns 221,355 shares of the medical research company’s stock valued at $29,781,000 after purchasing an additional 210,343 shares in the last quarter. First Hawaiian Bank bought a new stake in shares of Charles River Laboratories Intl. during the 3rd quarter valued at about $778,000. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Charles River Laboratories Intl. by 125.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 12,632 shares of the medical research company’s stock valued at $1,700,000 after purchasing an additional 7,032 shares in the last quarter. Hedge funds and other institutional investors own 94.10% of the company’s stock.

Charles River Laboratories Intl. stock traded down $0.91 during midday trading on Friday, reaching $140.22. 22,159 shares of the company’s stock were exchanged, compared to its average volume of 373,163. Charles River Laboratories Intl. has a 52 week low of $101.58 and a 52 week high of $141.99. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.38 and a current ratio of 1.61. The stock has a market capitalization of $6.79 billion, a P/E ratio of 23.25, a PEG ratio of 1.82 and a beta of 0.99.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: How to read a candlestick chart

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply